omarigliptin potent longacting oral antidiabetic drug inhibitor class used onceweekly treatment type diabetes currently development merck inhibits increase incretin levels inhibit glucagon release turn increases insulin secretion decreases gastric emptying decreases blood glucose levels marizev omarigliptin mg mg tablets approved japans pharmaceuticals medical devices agency pmda sept japan first country approved however merck announced company submit marketing application us drug article relating gastrointestinal system stub help wikipedia expanding ithttpsenwikipediaorgwikiomarigliptin